EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round

EQT Netherlands

EQT Life Sciences has invested in Asceneuron's oversubscribed Series C and Prof. Philip Scheltens will join the Asceneuron Board of DirectorsAsceneuron - which is developing small molecules targeting tau protein aggregation, a root cause of neurodegenerative disease - will use the funds to progress its lead asset ASN51 into Phase 2 clinical development for the treatment of Alzheimer's disease 

 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/eqt-life-sciences-invests-in-asceneuron--a-neurodegeneration-therapeutics-company--as-part-of-usd-10,c4015133

The following files are available for download:

https://mb.cision.com/Main/87/4015133/2916296.pdf

PR_EQT invests in Asceneuron_16.07.24

https://news.cision.com/eqt/i/neurons,c3320033

neurons

 

View original content:https://www.prnewswire.co.uk/news-releases/eqt-life-sciences-invests-in-asceneuron-a-neurodegeneration-therapeutics-company-as-part-of-usd-100-million-series-c-financing-round-302197836.html